Inhibitory Effects of Melicope ptelefolia Extract on Compound Action Potentials in Frog Sciatic Nerves and Its Possible Mechanism of Action
(Kesan Perencat Ekstrak Melicope ptelefolia pada Potensi Tindakan Sebatian dalam Saraf Skiatik Katak dan Tindakan Mekanisme Kemungkinan)

JASMINE SI EW MIN CHIA, AMMAR IZZATI AMIR RAMADAN, FA R IAH HANANI GH AZ A L I, SIONG J I UN WONG, MOHD ROSLAN SULAIMAN, TENGKU AZAM SHAH TENGKU MOHAMAD, MOHD KHAIRI HUSSAIN & ENOCH KUM AR PERIMAL*

ABSTRACT
Melicope ptelefolia is a medicinal plant from the Rutaceae, also known as 'tenggek burung' in Malaysia. Traditionally, natives ingest M. ptelefolia to treat a wide range of illnesses. This study aimed to investigate the effects of M. ptelefolia aqueous extract (MPAE) on compound action potentials (CAPs) in frog sciatic nerves and its mechanism involving the opioid receptors. The effects of MPAE on CAPs in frog sciatic nerves were examined using the AD Instrument Nerve Chamber. The frog sciatic nerves were dissected from the lumbar plexus to the knee of the frog and placed in Ringer’s solution. Three treatment groups with different dosages (1, 3 and 10 mg/mL) of MPAE, including negative (vehicle) and positive control group (3 mg/mL of morphine) were tested on the frog sciatic nerves by placing them in a nerve organ chamber. Following this, the involvement of opioid receptors in the effects of MPAE on CAPs was investigated by using naloxone hydrochloride as a non-selective opioid receptor antagonist. Our results showed that the peak amplitudes of CAPs were significantly (p<0.001) reduced when treated with MPAE (3 and 10 mg/mL) in frog sciatic nerves. The MPAE-induced CAPs inhibition was reversed when pre-treated with naloxone, suggesting the involvement of the opioidergic system. These results indicated the modulatory action of MPAE on nerve conduction, which may provide important leads in the development of new therapeutic drugs through the involvement of opioid receptors.

Keywords: Compound action potential; frog sciatic nerves; opioidergic; opioid receptors; Melicope ptelefolia

INTRODUCTION
Excitation of nerve cells results in a momentary change in membrane potential, resulting in the propagation of nerve signals. This interaction between extracellular substance and intracellular medium is known as action potential (Bogatov et al. 2014). Compound action potential (CAP) is the combined propagation of nerve signals of a group of fibres of cell. Peripheral nerves produce CAPs in both proximal and distal sites in the presence of a stimulus. Measurements such as action potential amplitudes and conduction velocity in different nerve segments can be graphically analyzed from CAPs (Li 2015).

As modern medicine may manifest many undesirable side effects, more research on natural product is required.

http://dx.doi.org/10.17576/jsm-2019-4808-07

One of the natural products is *Melicope ptelefolia* which is a medicinal plant from the Rutaceae family, known as ‘tenggek burung’, ‘pauh-pauh’ and also ‘cabang tiga’ in Malaysia. This plant is claimed by the natives to treat fever, pain, wounds and itches (Karim et al. 2011). Previous studies have stated that *M. ptelefolia* leaf extract has anti-inflammatory, analgesic and antinociceptive properties (Sulaiman et al. 2010). Inhibition of nerve conduction is one of the mechanisms on pain modulation. Therefore, *M. ptelefolia* may give inhibitory effect on CAPs as it has already shown antinociceptive properties.

In this study, naloxone hydrochloride was used as a non-selective opioid receptor antagonist to determine the involvement of opioid receptors in the effects of MPAE. The opioid receptor subtypes namely Mu (μ), Delta (δ), and Kappa (κ), are often targeted for pain treatments (Al-Hasani & Bruchas 2011). Activation of opioid receptors typically inhibits transmission of action potentials. Thus, usage of an opioid receptor antagonist often provides preliminary results on whether a compound acts through opioid receptors. Excited neuronal transmission of action potentials will occur at a constant rate if a certain compound elicits its effects without involvement of opioid receptors.

However, to the best of our knowledge, there is still no report examining the actions of *Melicope ptelefolia* aqueous extract (MPAE) on nerve conduction. Therefore, this study aimed to investigate the effects of MPAE on CAPs in frog sciatic nerves and its mechanism involving the opioidergic system. The results of this study will highlight the underlying activity of *M. ptelefolia* extract as an analgesic emphasising the use of natural products for clinical practice.

**MATERIALS AND METHODS**

**PLANT EXTRACTION**

Fresh leaves of *M. ptelefolia* were bought from Pasar Borong, Serdang, Selangor, Malaysia. The fresh leaves were identified and authenticated by a resident botanist through comparison with herbarium specimens of *M. ptelefolia* (SK 3071/16) kept at the Mini Herbarium, Institute of Bioscience, Universiti Putra Malaysia (UPM). The aerial parts of the plants, including the stems and leaves were washed and oven-dried for 48 h at 40°C. Dried leaves were ground and stored at -20°C. The powdered leaves were heated at about 80°C with an extraction ratio of approximately 1:10 of distilled water. The MPAE was freeze-dried for 3 days and stored at 4°C until further use.

**EXPERIMENTAL ANIMALS**

*Rana catesbeiana* frogs of either sex, weighing 200 to 300 g, were used in this experiment. All the experiments were conducted in accordance with the ethical guidelines on animal experimentation. The protocols and procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Universiti Putra Malaysia (Ref: UPM/IACUC/AUP-U001/2017). All efforts were made to minimise animal suffering and the number of animals used.

**DRUG PREPARATION**

*M. ptelefolia* aqueous extract (MPAE) (1, 3 and 10 mg/mL) was used as treatment in this experiment. Vehicle group received a mixture of 95% normal saline and 5% Tween 20. Morphine (3 mg/mL, 10 mM) was used as the positive control. Naloxone hydrochloride (0.1 mg/mL, 0.27 mM), a non-selective opioid receptor antagonist, was used to study the involvement of opioidergic system. Ringer’s solution (NaCl, 115.5 mM; KCl, 2.0 mM; CaCl₂, 1.8 mM; Na₂HPO₄, 1.3 mM; and NaH₂PO₄, 0.7 mM (pH = 7.0)) was used as temporary medium to keep the sciatic nerves before CAP measurement procedures.

**EXPERIMENTAL DESIGN**

For the first set of experiment, the effects of MPAE on CAPs were evaluated whereas the involvement of the opioidergic pathway was investigated as the second set of experiment. The experimental timeline and treatment groups are as shown in Figure 1 and Table 1, respectively.

**PREPARATION OF FROG SCIATIC NERVES**

The method used for isolation and preparation of frog sciatic nerves was as previously described (Katsuki et al. 2006; Kosugi et al. 2010; Mizuta et al. 2008). Frogs were decapitated and then pithed; the sciatic nerves were dissected from the lumbar plexus to the knee. Throughout dissections, Ringer’s solution was continuously applied to the nerves to keep it moist. Sciatic nerves were kept in Ringer’s solution before measuring the CAPs.

**RECORDINGS OF CAPS FROM FROG SCIATIC NERVE**

CAPs were recorded using AD Instrument Nerve Chamber and LabTutor Software. The frog sciatic nerve was placed at the center of the chamber and the nerve was stimulated for recording of CAPs. The stimulation was started at 10 mV and measurements were recorded when the voltage reached 200 mV. CAPs were recorded before and after exposure to their respective experimental group treatments. The relative peak amplitude of CAPs was measured as the difference between baseline and CAPs peak levels (Yao et al. 2015). All procedures were performed quickly to avoid losing moisture of the sciatic nerve.

**EFFECTS OF MPAE ON CAPS**

The effects of MPAE were determined by using 5 experimental groups, which were the negative control (vehicle), MPAE treatment (1, 3 and 10 mg/mL) and positive control (morphine, 3 mg/mL). The CAPs of frog sciatic nerves were recorded before each treatment
procedure. Sciatic nerves were soaked with respective treatments according to their experimental groups for 30 min.

**INVOLVEMENT OF OPIOIDERIC SYSTEM**

The involvement of opioidergic system was investigated using four experimental groups which were negative control (vehicle), MPAE treatment (3 mg/mL), naloxone hydrochloride (0.1 mg/mL) and MPAE (3 mg/mL) with naloxone hydrochloride group. Sciatic nerves (n=6) were pre-treated with naloxone hydrochloride (0.1 mg/mL) for 20 min prior to soaking in MPAE (3 mg/mL) for 30 min.

**DATA ANALYSIS**

Data are presented in relative CAPs amplitude with mean ± S.E.M. and analysed using two-way ANOVA followed by Bonferroni’s post-hoc test. The values were analysed using GraphPad Prism v5.0 software (GraphPad San Diego, CA) and the statistical significance was set at p<0.05.

**RESULTS**

Table 1. Experimental treatment groups for sciatic nerves (n=6) collected from a total of 27 animals

<table>
<thead>
<tr>
<th>Experiment 1: Inhibitory effects of MPAE on CAPS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td>M. ptelefolia aqueous extract (MPAE)</td>
</tr>
<tr>
<td>1 mg/mL</td>
</tr>
<tr>
<td>3 mg/mL</td>
</tr>
<tr>
<td>10 mg/mL</td>
</tr>
<tr>
<td>Morphine</td>
</tr>
<tr>
<td>3 mg/mL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Experiment 2: Involvement of opioidergic pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
</tr>
<tr>
<td>-</td>
</tr>
<tr>
<td>MPAE</td>
</tr>
<tr>
<td>3 mg/mL</td>
</tr>
<tr>
<td>Naloxone hydrochloride</td>
</tr>
<tr>
<td>0.1 mg/mL</td>
</tr>
<tr>
<td>MPAE + Naloxone hydrochloride</td>
</tr>
<tr>
<td>3 + 0.1 mg/mL</td>
</tr>
</tbody>
</table>

Figure 1. (A) Experiment 1: Investigating the inhibitory effects of MPAE on CAPs and (B) Experiment 2: Investigating the involvement of the opioidergic system in the inhibitory effects of MPAE.
CAPS of 25.0±1.6 mV. Complete recovery of CAPs peak amplitude was achieved after washing out the sciatic nerves for 30 min.

**EFFECTS OF *Melicope ptelefolia* AQUEOUS EXTRACT IN FROG SCIATIC NERVES CAPS**

The effects of MPAE on frog sciatic nerves were examined by soaking the nerves in three different dosages, which were 1, 3 and 10 mg/mL. Inhibitory effects of the three dosages of MPAE as shown in Figure 2, were compared with controls. Reduction in CAPs peak amplitude was dose-dependent when treated with MPAE at 1, 3 and 10 mg/mL, where 3 and 10 mg/mL showed almost similar inhibition to CAPs peak amplitude. MPAE effects at 3 mg/mL (14.2±1.4 mV; n=6) and 10 mg/mL (11.9±0.9 mV; n=6) were both significantly different (p<0.001) after treatment when compared to vehicle (21.0±2.2 mV; n=6).

In order to compare the effects of MPAE with other established analgesics, we investigated the effects of morphine (3 mg/mL) on CAPs peak amplitudes. Following exposure of sciatic nerves to morphine, CAPs amplitude significantly reduced (12.3±0.7 mV; n=6, P < 0.001) as shown in Figure 2. The reduction of CAPs amplitude 30 min after exposure of respective treatments was not significantly different between MPAE (3 and 10 mg/mL) and morphine (3 mg/mL) where the CAPs amplitudes were 14.2±1.4 mV, 11.9±0.9 mV and 12.3±0.7 mV, respectively.

Traces of the nerves soaked in 3 mg/mL of MPAE reducing the CAPs amplitude were compared to control (vehicle) as shown in Figure 3 demonstrates the relative CAPs amplitudes of MPAE (3 mg/mL) with maximal reduction effects were observed after 30 min of treatment (Figure 4). After the washing process, CAPs increased and returned to normal as the control after 60 min.

**EFFECT OF OPIOID RECEPTOR ANTAGONIST IN FROG SCIATIC NERVES CAPS**

Naloxone hydrochloride, a non-specific opioid receptor antagonist, was used to determine the involvement of the opioidergic system in the MPAE-induced reduction of CAPs amplitude. Traces between the control, naloxone and naloxone with MPAE were compared between groups (Figure 5). Pre-treatment with naloxone alone did not significantly affect the CAPs. As shown in Figure 6, the reversible inhibition of MPAE at 3 mg/mL occurred in the presence of an opioid receptor antagonist. Following exposure to naloxone (0.1 mg/mL) for 20 min with MPAE treatment (21.9±1.5 mV; n=6), the CAPs amplitude was significantly different from results obtained by treatment of MPAE alone (14.2±1.4 mV; n=6, p<0.001).

![Figure 2](image_url)  
**FIGURE 2.** Changes in relative CAPs amplitudes of sciatic nerves in control, *Melicope ptelefolia* aqueous extract (MPAE) at 1, 3 and 10 mg/mL and morphine treated groups 30 min following soaking. Each point represented CAPs peak amplitude following exposure to respective treatment, relative to values obtained prior to soaking, in six sciatic nerves.

![Figure 3](image_url)  
**FIGURE 3.** Comparison of CAPs amplitude curves between control and MPAE (3 mg/mL) treatment 30 min after soaking. The MPAE curve obtained at 30 min has lower peak amplitude compared to the control, with the peak returning to normal after 30 min of washing.
FIGURE 4. Average time course changes in CAPs peak amplitudes from sciatic nerves soaked in MPAE (3 mg/mL) over a period of 60 min. After the washing process, the relative CAP amplitudes returned to normal at 60 min. Each point represented CAPs peak amplitude following exposure to MPAE (3 mg/mL) and washing, relative to values obtained prior to soaking, in six sciatic nerves.

FIGURE 5. Comparison of CAPs amplitude curves between control, naloxone hydrochloride and naloxone hydrochloride pre-treated prior to MPAE (3 mg/mL) 30 min after soaking. Exposure of the sciatic nerves to naloxone hydrochloride, a non-selective opioid receptor antagonist, prevented the inhibitory effects of MPAE on CAPs peak amplitude.

FIGURE 6. Average time course changes in CAPs peak amplitudes from sciatic nerves pre-treated with naloxone hydrochloride, a non-selective opioid receptor antagonist, prior to soaking with MPAE (3 mg/kg) over a period of 60 min. Exposure to naloxone 20 min prior to treatment reverses the inhibitory effect of MPAE to CAPs peak amplitude. Each point represented CAPs peak amplitude following exposure to naloxone and MPAE (3 mg/mL), relative to values obtained prior to soaking, in six sciatic nerves.
DISCUSSION

This study was carried out to investigate the effects of MPAE on CAPS in frog sciatic nerves, tested with three different dosages. To ensure absence of error or bias in recording of CAPS amplitudes, the setup was tested daily before recording by placing the filter paper soaked with Ringer’s solution. The *M. ptelefolia* aqueous extract (MPAE) was dissolved in 95% of normal saline and 5% of Tween 20. The sciatic nerves treated with vehicle were recorded and acted as the negative control to ensure the inhibition of CAPS during MPAE treatment was caused by the extract itself.

This study was the first to show the effects of MPAE on nerve conduction through inhibition on CAPS amplitudes, which was dose-dependent in the range of 1 to 10 mg/mL. Based on the results, CAPS gradually decreased across the period of soaking in all three dosages of MPAE. The sciatic nerves soaked in 10 mg/mL of MPAE gave the maximal inhibition on CAPS at 30 min with 50% inhibition whereas MPAE at 3 mg/mL had almost 50% inhibition on CAPS. Morphine (3 mg/mL) was significantly different when compared to vehicle, where a 40% reduction of CAPS was observed (p<0.001). As the effects of 3 mg/mL of MPAE on CAPS were as strong as 10 mg/mL, therefore 3 mg/mL of MPAE was chosen as the optimum dose for Experiment 2.

The effect of MPAE inhibition on CAPS could occur through nonspecific membrane bilayer interactions or through inhibition of tetraethylammonium(TEA)-sensitive K+ channels and/or tetrodotoxin(TTX)-sensitive voltage-gated Na+ channels (Mizuta et al. 2008). The intensity of CAPS amplitude relies on the influx of Na+, efflux of K+ and the resting potential level. The involvement of these ion channels could be observed from the CAPS graph whereby the rise period of action potential represents Na+-dependent parameters and repolarisation period represents K+ efflux-dependent parameters (Pandey & Deshpande 2012). Further studies on how MPAE interacts with Na+ and K+ channels should be conducted.

Our results showed that the effects of MPAE on sciatic nerves CAPS were inhibited when pre-treated with naloxone (0.1 mg/mL). As there was no significant difference in CAPS amplitudes across the time (0-50 min), opioid receptors may be involved in the inhibitory effects of MPAE on nerve conduction. A study by Uemura et al. (2014) showed that analgesics exert their antinociceptive effects through inhibition of nerve action potential conduction. Previous study on the *M. ptelefolia* extract in an animal model of antinociception exhibited analgesic properties (Sulaiman et al. 2010). The ability of MPAE to reduce CAPS amplitude is therefore correlated with inhibition of nerve conduction, which indirectly alleviates pain (Sandkühler 2000). The opioidergic system is one of the highly important pain modulatory systems in the pain pathway and the effects of MPAE on CAPS amplitude may have been mediated by opioid receptors. Previous studies on opioids showed reduction on CAPS amplitudes due to the presence of opioid receptors on nerve fibres (Fields et al. 1980; Gissen et al. 1987; Jaffe & Rowe 1996). The inhibitory effect of morphine is highly sensitive to the presence of naloxone, which antagonised the CAPS amplitude reduction, demonstrating the involvement of opioid receptors (Jurna & Grossman 1977).

There are various pathways and receptors that may cause an effect towards CAPS. In this paper, we showed that MPAE activity on nerve conduction was influenced by opioid receptors. Exogenous opioids for example, do not exert its inhibitory effects solely through opioid receptors. Güven et al. (2005) reported that tramadol, a centrally acting opioid, has low affinity to opioid receptors. Instead, tramadol inhibits peripheral nerve conduction via blockade of Na+ and K+ channels. Thus, it is possible that other receptors and channels influence MPAE-induced CAPS inhibition.

CONCLUSION

In summary, the present study showed that *M. ptelefolia* aqueous extract (MPAE) has the ability to modulate nerve conduction by inhibiting CAPS. Inhibitory mechanism, particularly through the involvement of the opioidergic system was demonstrated with 3 mg/mL of MPAE. Our findings indicated that MPAE has high potential as a naturally sourced analgesic where it could serve in both nutraceutical and drug industries.

ACKNOWLEDGEMENTS

The authors thank the Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, and the Physiology Laboratory for providing the necessary support for the study. This project was supported by Universiti Putra Malaysia under the Putra Young Initiative (IPM) Grant (GP-IPM/2014/9433700).

REFERENCES


Department of Biomedical Sciences, Faculty of Medicine and Health Sciences Universiti Putra Malaysia 43400 Serdang, Selangor Darul Ehsan Malaysia

*Corresponding author; email: enoch@upm.edu.my

Received: 17 May 2018
Accepted: 15 May 2019